Views equals page views plus PDF downloads
At its October 2020 meeting, the Advisory Committee on Immunization Practices* (ACIP) approved the 2021 Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger. After Emergency Use Authorization of Pfizer-BioNTech COVID-19 vaccine by the Food and Drug Administration (FDA), ACIP issued an interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine in persons aged ≥16 years at its December 12, 2020, meeting (1). In addition, ACIP approved an amendment to include COVID-19 vaccine recommendations in the child and adolescent immunization schedule. After Emergency Use Authorization of Moderna COVID-19 vaccine by FDA, ACIP issued an interim recommendation for use of Moderna COVID-19 vaccine in persons aged ≥18 years at its December 19, 2020, emergency meeting (2).
The 2021 child and adolescent immunization schedule summarizes ACIP recommendations, including several changes from the 2020 immunization schedule† on the cover page, two tables, and notes found on the CDC immunization schedule website (https://www.cdc.gov/vaccines/schedules). Health care providers are advised to use the tables and the notes together. This immunization schedule is recommended by ACIP (https://www.cdc.gov/vaccines/acip) and approved by CDC (https://www.cdc.gov), the American Academy of Pediatrics (https://www.aap.org), the American Academy of Family Physicians (https://www.aafp.org), the American College of Obstetricians and Gynecologists (https://www.acog.org), the American College of Nurse-Midwives (https://www.midwife.org), the American Academy of Physician Assistants (https://www.aapa.org), and the National Association of Pediatric Nurse Practitioners (https://www.napnap.org).
ACIP’s recommendations on use of each vaccine are developed after in-depth reviews of vaccine-related data, including the epidemiology and societal impacts, vaccine efficacy and effectiveness, vaccine safety, quality of evidence, feasibility of program implementation, and economic analyses of immunization policy (3). The child and adolescent immunization schedule is published annually to consolidate and summarize updates to ACIP recommendations on vaccination of children and adolescents, and to assist health care providers in implementing current ACIP recommendations. The use of vaccine trade names in this report and in the child and adolescent immunization schedule is for identification purposes only and does not imply specific product endorsement by ACIP or CDC.
For further guidance on the use of each vaccine, including contraindications and precautions, and any updates that might occur between annual updates to the child and adolescent immunization schedule, health care providers are referred to the respective ACIP vaccine recommendations at https://www.cdc.gov/vaccines/hcp/acip-recs.§ Printable versions of the 2021 child and adolescent immunization schedule and ordering instructions are available at https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html.
Changes in the 2021 Child and Adolescent Immunization ScheduleVaccine-specific changes in the 2021 child and adolescent immunization schedule for children and adolescents aged 18 years or younger include new or updated ACIP recommendations for influenza vaccine (4) meningococcal serogroups A, C, W, and Y (MenACWY) vaccines (5), and COVID-19 vaccines (1,2). Changes also include clarification of the recommendations for diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP), Haemophilus influenzae type b vaccine (Hib), hepatitis A vaccine (HepA), hepatitis B vaccine (HepB), human papillomavirus vaccine (HPV), pneumococcal vaccines (PCV13 and PPSV23), measles, mumps, and rubella virus vaccine (MMR), tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap), and varicella vaccine (VAR). Following are the changes to the cover page, Tables 1 and 3, and the Vaccine Notes.
Cover pageThe American Academy of Physician Assistants and the National Association of Pediatric Nurse Practitioners have been added to the list of organizations that approve the child and adolescent immunization schedule.
MenACWY-TT (MenQuadfi) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine (Vaxelis) have been added to the table of vaccine abbreviations/trade names.
The abbreviation for live attenuated influenza vaccine (LAIV) was changed to LAIV4.
HepB row: Arrows have been added to clarify the recommended ages for administering the second dose.
LAIV: The abbreviation was changed to LAIV4.
Legend: The text that defines the red box has been edited to include “Vaccinate after pregnancy.” The text now reads “Not recommended/contraindicated—vaccine should not be administered. *Vaccinate after pregnancy.”
LAIV: The abbreviation was changed to LAIV4.
MMR row: An asterisk has been added in the pregnancy column. The asterisk links to the descriptive text “*Vaccinate after pregnancy” in the red box of the table’s legend.
VAR row: An asterisk has been added in the pregnancy column. The asterisk links to the descriptive text “*Vaccinate after pregnancy” in the red box of the table’s legend.
HPV row: The color for the pregnancy column has been changed from pink to red; an asterisk has also been added. The asterisk links to the descriptive text “*Vaccinate after pregnancy” in the red box of the table’s legend.
• Additional Information: The section has been updated to include COVID-19 vaccination recommendations.
• DTaP: A “Special situations” section has been added that contains information regarding the recommendation for use of DTaP vaccine in wound management.
• Hib: Text has been added to clarify the recommendations for catch-up vaccination. A bullet has been added to indicate that no further doses are needed if a dose was administered at age ≥15 months.
• HepA: The note was updated to clarify information on the accelerated 4-dose series of combined HepA-HepB vaccine. The fourth dose at month 12 is a booster dose.
• HepB: Additional text has been added to emphasize the birth dose in the vaccination note. The sentence on recommendations for infants born to an HBsAg-negative mother and weighing <2,000 g has been updated with language to provide further clarification regarding when the vaccine can be administered.
• HepB: The note was updated to clarify information on the accelerated 4-dose series of combined HepA-HepB vaccine. The fourth dose at month 12 is a booster dose.
• HPV: The note has been updated to clarify that if the vaccination schedule is interrupted, the series does not need to be restarted.
• Influenza vaccination: The note has been updated to reflect the recommendations for the 2020–21 influenza season. The “Special situations” section was updated with language for persons who have egg allergy with symptoms other than hives, and two new bullets were added with information on severe allergic reactions after influenza vaccination. The abbreviation LAIV was changed to LAIV4. In addition, the bullets that outline circumstances under which LAIV4 should not be used were updated to include children aged <2 years, and more detailed information on the use of LAIV4 after receipt of influenza antiviral medications to account for newer antivirals with longer half-lives was added.
• MenACWY: MenACWY-TT (MenQuadfi) has been added to the list of vaccines in the sections on routine vaccination, catch-up vaccination, and special situations. In addition, the “Special situations” section has been updated with information on the recommendations for the use of MenACWY-CRM (Menveo) in infants who received dose 1 at age 3–6 months.
• Pneumococcal vaccination: Text has been added to the “Special situations” section of the note to clarify the recommendations for administering PPSV23 after PCV13.
• Tdap: A “Special situations” section has been added to the note that contains information regarding the recommendation for use of Tdap vaccine in wound management.
AcknowledgmentsRosters of current and past members of the Advisory Committee on Immunization Practices (ACIP) are available at https://www.cdc.gov/vaccines/acip/committee/members-archive.html.
ACIP Combined Immunization Schedule Work GroupKevin Ault (co-Chair), Henry Bernstein (co-Chair). Members: Carolyn Bridges, Sarah Coles, Katherine Debiec, Marci Drees, John Epling, Holly Fontenot, Sandra Fryhofer, Kathleen Harriman, Robert Hopkins, Molly Howell, Paul Hunter, Karen Ketner, David Kim, Jane Kim, Marie-Michelle Leger, Susan Lett, Veronica McNally, Sarah McQueen, Amy B. Middleman, Sean O’Leary, Diane Peterson, Chad Rittle, William Schaffner, Ken Schmader, Rhoda Sperling, Peter Szilagyi, Patricia Stinchfield, L.J. Tan, Thomas Weiser. Contributors: A. Patricia Wodi (CDC co-Lead), Mark Freedman (CDC co-Lead); CDC Contributors: Kathy Byrd, Amanda Cohn, Kathleen Dooling, Amy Parker-Fiebelkorn, Lisa Grohskopf, Fiona Havers, Holly Hill, Tara Jatlaoui, Suzanne Johnson-DeLeon, Miwako Kobayashi, Ram Koppaka, Andrew Kroger, Lucy McNamara, Jessica MacNeil, Lauri Markowitz, Elissa Meites, Tina Objio, Sara Oliver, Priti Patel, Tamara Pilishvili, Ginger Redmon, Sarah Schillie, Cindy Weinbaum Walter Williams, Akiko Wilson, JoEllen Wolicki.
Corresponding author: A. Patricia Wodi, awodi@cdc.gov, 404-498-6431.
1Immunization Services Division, National Center for Immunization and Respiratory Diseases, CDC; 2University of Kansas Medical Center, Kansas City, Kansas; 3Department of Family Medicine and Community Health, University of Wisconsin, Madison, Wisconsin; 4Fanny Strong Foundation, West Bloomfield, Michigan; 5Department of Pediatrics, University of California Los Angeles, Los Angeles, California; 6Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York; 7Department of Pediatrics, Cohen Children’s Medical Center, New Hyde Park, New York.
ReferencesSuggested citation for this article: Wodi AP, Ault K, Hunter P, McNally V, Szilagyi PG, Bernstein H. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger — United States, 2021. MMWR Morb Mortal Wkly Rep 2021;70:189–192. DOI: http://dx.doi.org/10.15585/mmwr.mm7006a1.
MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Department of Health and Human Services.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.
All HTML versions of MMWR articles are generated from final proofs through an automated process. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (https://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables.
Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.
RetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.3